A phase I, prospective, open label clinical study to assess the safety and tolerability of DTaP-IPV+Hib vaccine manufactured by Serum Institute of India Pvt. Ltd. in healthy adult volunteers

Trial Profile

A phase I, prospective, open label clinical study to assess the safety and tolerability of DTaP-IPV+Hib vaccine manufactured by Serum Institute of India Pvt. Ltd. in healthy adult volunteers

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Hib-DTaP-poliovirus vaccine (Primary)
  • Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Adverse reactions
  • Sponsors Serum Institute of India
  • Most Recent Events

    • 14 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top